C-RAD Sentinel is a new system for surface contour localization and monitoring of the patient in the radiotherapy treatment process.

The C-RAD Sentinel basic platform is based on advanced laser technology with multipurpose software modules covering different tasks in the treatment procedure. The different software modules are integrated with other systems in the clinic.

August 1, 2008 – The Centers for Medicare & Medicaid Services (CMS) yesterday issued a final ruling for three new hospital errors or conditions it will no longer pay for, including: surgical site infections following certain elective procedures, including certain orthopedic surgeries, and bariatric surgery for obesity; certain manifestations of poor control of blood sugar levels; and deep vein thrombosis or pulmonary embolism following total knee replacement and hip replacement procedures.

August 1, 2008 – BSD Medical Corp. said its BSD-2000/3D/MR cancer treatment system has been adapted to treat children with cancer.

To accommodate the treatment of children, BSD has developed treatment applications specifically sized for small and medium-sized children and that are capable of delivering pediatric cancer therapy during simultaneous magnetic resonance imaging (MRI) during the treatment process.

August 1, 2008 - Healthcare professionals need an authoritative resource on the Internet designed to quickly provide answers to urgent treatment questions, so Epocrates partnered with BMJ Group, publisher of the British Medical Journal, to create a new online product that delivers practical and up-to-date disease diagnosis and treatment guidelines.

July 31, 2008 - Bristol-Myers Squibb Co. today offered $4.5 billion in cash for its cancer drug partner, ImClone Systems, a biotechnology company that makes ERBITUX (Cetuximab), a drug used in combination with radiation therapy for the treatment of advanced head and neck cancers.

ImClone’s board has not commented on the proposal, which offers its stockholders $60 per share, a 30 percent premium to New York-based ImClone's closing price of $46.44 Wednesday. New York-based Bristol-Myers already owns about 17 percent of ImClone.

Xoft Inc. recently received FDA clearance for applicators to be used with the Axxent Electronic Brachytherapy System for the treatment of endometrial cancer.

Previously cleared for accelerated treatment of early stage breast cancer, the Axxent System, a proprietary technology platform designed to deliver localized, non-radioactive, isotope-free radiation treatment in minimally-shielded clinical settings, also recently received expanded FDA clearance for use in the treatment of other cancers or conditions where radiation therapy is indicated.

Nucletron said the FDA cleared its Oncentra Brachy, a comprehensive volume-based treatment planning solution designed to optimize cancer treatment planning with brachytherapy.

Elekta recently received FDA clearance for its Volumetric Modulated Arc Therapy (VMAT).

Reportedly empowering clinicians to treat more patients in significantly less time, Elekta VMAT offers the clinical efficacy of IMRT delivered in a fraction of the time, providing rapid treatment with daily 3D image guidance. Features of VMAT include faster treatment times, precise dose control, reduced radiation dose to healthy tissue and 3D Volumetric imaging.

The Piranha and Barracuda reportedly offer a complete range of capabilities to measure the important QA parameters on all types of X-ray systems. Both are based on solid-state technology. The Barracuda has available bias voltage for the use of ionization chambers.

BrainLAB said it received 510(k) clearance for its Monte Carlo Dose Calculation Algorithm, which is already being used at several clinical cooperation sites worldwide.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now